Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

KM Biologics Announces Phase I Clinical Study Results of a Live Attenuated Tetravalent Dengue Vaccine (KD-382)

03/25/2021 | 12:24am EDT

KM Biologics Co., Ltd. (Headquarters: Kumamoto, Japan; CEO: Toshiaki Nagasato) announced the results of the Phase I clinical study (hereinafter the “Study”) of a live attenuated tetravalent vaccine, KD-382*1 (hereinafter, the “KD-382 vaccine”), to prevent dengue*2.

This study was conducted to evaluate the safety and immunogenicity of the KD-382 vaccine in 60 healthy adults in Australia, which is a non-dengue endemic country, by administering the KD-382 vaccine subcutaneously once or twice with a 4-week interval.

The results show that the KD-382 vaccine is safe and well-tolerated by healthy adults. Moreover, KD-382 showed 100% seroconversion at an early stage and elicited long-lasting and neutralizing antibody response for all 4 serotypes in most subjects over a 1-year follow-up, despite the single-dose administration.

Based on the supporting results indicating the KD-382 vaccine as very promising, we will proceed with preparations for Phase II clinical studies of the KD-382 vaccine in dengue-endemic countries to maximize the value of the vaccine and address the unmet medical needs of people at risk of dengue worldwide.

*1

KD-382 is a live attenuated tetravalent dengue vaccine that is expected to be effective against all four serotypes with a single dose. As a live attenuated virus vaccine is expected to induce both neutralizing antibodies and cellular immunity, similar to natural infection, the long-term persistence of neutralizing antibodies and low probability of disease enhancement due to antibody-dependent enhancement (ADE) can be expected.

 

 

*2

Dengue virus is a mosquito-borne virus belonging to the Flaviviridae family and causes dengue fever, dengue hemorrhagic fever, and dengue shock syndrome in humans. Four serotypes, ranging from type 1 to type 4, are involved in human epidemics. Dengue is endemic in more than 120 countries in tropical and subtropical regions. Approximately 50% of the world’s population, or 3.9 billion people, are at risk of infection, and approximately 100 million people become infected each year. It was estimated that in 2010, 390 million people were infected, and 96 million people required hospitalization and other treatments. In addition, 500,000 people require hospitalization owing to severe illness every year because of dengue fever or dengue hemorrhagic fever, and the annual mortality rate is estimated to be 2.5% (12,500 people) (WHO report).

 


© Business Wire 2021
Latest news "Companies"
05:51aADNOC Logistics and Services Continues Strategic Expansion with Acquisition of Two Additional VLCCs
PU
05:51aGOLDPAC  : Proposed declaration of final dividend and special dividend, re-election of retiring directors, grant of general mandates to issue and buy back shares, proposed adoption of the new articles of association and notice of annual general meeting
PU
05:51aSHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Nomura Holdings, Inc. - NMR
PR
05:49aPARAGON BANKING  : Foxley to bring iconic St Albans buildings back to life after securing £8.5 million funding
PU
05:49aSHENG YE CAPITAL  : Discloseable transaction - disposal of accounts receivable
PU
05:49aBLACKROCK WORLD MINING TRUST  : Statement re Disclosure of Portfolio Holdings
PR
05:48aSTHREE  : Issue of Shares
DJ
05:47aCITIC RESOURCES  : Change of chief financial officer
PU
05:47aROAD KING INFRASTRUCTURE  : Form of proxy for use at the Annual General Meeting (or at any adjournment thereof)
PU
05:47aSEVERFIELD  : Going that extra mile
PU
Latest news "Companies"